Effect of pharmacological interventions on the fronto-cingulo-parietal cognitive control network in psychiatric disorders: A transdiagnostic systematic review of fMRI studies

Frontiers in Psychiatry

Volumn 7, Issue MAY, 2016, Pages

  van Amelsvoort, Thérèse ^a   Hernaus, Dennis ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Attention; Cognition; Executive functioning; FMRI; Prefrontal cortex; Psychiatric disorders; Psychopharmacology; Treatment

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CITALOPRAM; DONEPEZIL; ESCITALOPRAM; FLUOXETINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TOLCAPONE; VALPROATE SEMISODIUM; VARENICLINE; VENLAFAXINE; ZIPRASIDONE;

ACCURACY; ALCOHOLISM; ANTERIOR CINGULATE; ATTENTION; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; DEPRESSION; DORSOLATERAL PREFRONTAL CORTEX; DRUG EFFECT; DRUG MECHANISM; ELECTROENCEPHALOGRAM; EXECUTIVE FUNCTION; FRONTO CINGULO PARIETAL COGNITIVE CONTROL NETWORK; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; INFERIOR FRONTAL GYRUS; INSULA; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MOOD DISORDER; MULTICENTER STUDY (TOPIC); NERVE CELL NETWORK; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PHARMACEUTICAL CARE; PREDICTIVE VALUE; PREFRONTAL CORTEX; PSYCHOPHARMACOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE TIME; REVIEW; SUBGENUAL ANTERIOR CINGULATE CORTEX; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT DURATION; VENTROLATERAL PREFRONTAL CORTEX; VENTROMEDIAL PREFRONTAL CORTEX;

EID: 84975758679     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2016.00082     Document Type: Review

References (177)

1. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull (2013) 139(1):81-132. doi:10.1037/a0028727
2. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med (2014) 44(10):2029-40. doi:10.1017/S0033291713002535
3. Bora E, Yucel M, Pantelis C. Cognitive impairment in affective psychoses: a meta-analysis. Schizophr Bull (2010) 36(1):112-25. doi:10.1093/schbul/sbp093
4. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr Res (2014) 158(1-3):156-62. doi:10.1016/j.schres.2014.06.034
5. Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med (2008) 38(6):771-85. doi:10.1017/S0033291707001675
6. Lee RS, Hermens DF, Scott J, Redoblado-Hodge MA, Naismith SL, Lagopoulos J, et al. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. J Psychiatr Res (2014) 57:1-11. doi:10.1016/j.jpsychires.2014.06.019
7. Morein-Zamir S, Craig KJ, Ersche KD, Abbott S, Muller U, Fineberg NA, et al. Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation. Psychopharmacology (2010) 212(3):357-67. doi:10.1007/s00213-010-1963-z
8. Segalas C, Alonso P, Labad J, Jaurrieta N, Real E, Jimenez S, et al. Verbal and nonverbal memory processing in patients with obsessive-compulsive disorder: its relationship to clinical variables. Neuropsychology (2008) 22(2):262-72. doi:10.1037/0894-4105.22.2.262
9. Kopera M, Wojnar M, Brower K, Glass J, Nowosad I, Gmaj B, et al. Cognitive functions in abstinent alcohol-dependent patients. Alcohol (2012) 46(7):665-71. doi:10.1016/j.alcohol.2012.04.005
10. van Holst RJ, Schilt T. Drug-related decrease in neuropsychological functions of abstinent drug users. Curr Drug Abuse Rev (2011) 4(1):42-56. doi:10.2174/1874473711104010042
11. O'Toole MS, Pedersen AD. A systematic review of neuropsychological performance in social anxiety disorder. Nord J Psychiatry (2011) 65(3):147-61. doi:10.3109/08039488.2011.565801
12. Robinson S, Goddard L, Dritschel B, Wisley M, Howlin P. Executive functions in children with autism spectrum disorders. Brain Cogn (2009) 71(3):362-8. doi:10.1016/j.bandc.2009.06.007
13. Verte S, Geurts HM, Roeyers H, Oosterlaan J, Sergeant JA. Executive functioning in children with an autism spectrum disorder: can we differentiate within the spectrum? J Autism Dev Disord (2006) 36(3):351-72. doi:10.1007/s10803-006-0074-5
14. Joseph MF, Frazier TW, Youngstrom EA, Soares JC. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J Child Adolesc Psychopharmacol (2008) 18(6):595-605. doi:10.1089/cap.2008.064
15. Schoechlin C, Engel RR. Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol (2005) 20(6):727-44. doi:10.1016/j.acn.2005.04.005
16. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry (2012) 69(6):562-71. doi:10.1001/archgenpsychiatry.2011.1592
17. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med (2006) 36(8):1119-29. doi:10.1017/S0033291706007896
18. Tarter RE, Kirisci L, Mezzich A, Cornelius JR, Pajer K, Vanyukov M, et al. Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder. Am J Psychiatry (2003) 160(6):1078-85. doi:10.1176/appi.ajp.160.6.1078
19. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord (2011) 134(1-3):20-31. doi:10.1016/j.jad.2010.11.011
20. Daglas R, Yucel M, Cotton S, Allott K, Hetrick S, Berk M. Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. Int J Bipolar Disord (2015) 3:9. doi:10.1186/s40345-015-0024-2
21. McAuley T, Crosbie J, Charach A, Schachar R. The persistence of cognitive deficits in remitted and unremitted ADHD: a case for the state-independence of response inhibition. J Child Psychol Psychiatry (2014) 55(3):292-300. doi:10.1111/jcpp.12160
22. Majer M, Ising M, Kunzel H, Binder EB, Holsboer F, Modell S, et al. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med (2004) 34(8):1453-63. doi:10.1017/S0033291704002697
23. Gruber SA, Rosso IM, Yurgelun-Todd D. Neuropsychological performance predicts clinical recovery in bipolar patients. J Affect Disord (2008) 105(1-3):253-60. doi:10.1016/j.jad.2007.04.014
24. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry (2006) 163(3):418-25. doi:10.1176/appi.ajp.163.3.418
25. Miller M, Hinshaw SP. Does childhood executive function predict adolescent functional outcomes in girls with ADHD? J Abnorm Child Psychol (2010) 38(3):315-26. doi:10.1007/s10802-009-9369-2
26. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord (2000) 60(1):13-23. doi:10.1016/S0165-0327(99)00157-3
27. Trampush JW, Lencz T, DeRosse P, John M, Gallego JA, Petrides G, et al. Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophr Bull (2015) 41(6):1237-47. doi:10.1093/schbul/sbv120
28. Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, et al. Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 37(10 Pt 1):2438-44. doi:10.1016/j.neubiorev.2013.03.022
29. Husain M, Mehta MA. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci (2011) 15(1):28-36. doi:10.1016/j.tics.2010.11.002
30. Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry (2014) 76(8):616-28. doi:10.1016/j.biopsych.2013.10.016
31. Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry (2013) 74(9):902-17. doi:10.4088/JCP.12r08287
32. Linssen AM, Sambeth A, Vuurman EF, Riedel WJ. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Int J Neuropsychopharmacol (2014) 17(6):961-77. doi:10.1017/S1461145713001594
33. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis (2013) 35(2):349-61. doi:10.3233/JAD-122140
34. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology (2008) 33(7):1477-502. doi:10.1038/sj.npp.1301534
35. Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol (2014) 28(9):837-46. doi:10.1177/0269881114542453
36. Desamericq G, SchurhoffF, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol (2014) 70(2):127-34. doi:10.1007/s00228-013-1600-y
37. Niendam TA, Laird AR, Ray KL, Dean YM, Glahn DC, Carter CS. Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cogn Affect Behav Neurosci (2012) 12(2):241-68. doi:10.3758/s13415-011-0083-5
38. Egner T, Hirsch J. Cognitive control mechanisms resolve conflict through cortical amplification of task-relevant information. Nat Neurosci (2005) 8(12):1784-90. doi:10.1038/nn1594
39. Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A (1996) 93(24):13473-80. doi:10.1073/pnas.93.24.13473
40. Bari A, Robbins TW. Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol (2013) 108:44-79. doi:10.1016/j.pneurobio.2013.06.005
41. Derrfuss J, Brass M, Neumann J, von Cramon DY. Involvement of the inferior frontal junction in cognitive control: meta-analyses of switching and Stroop studies. Hum Brain Mapp (2005) 25(1):22-34. doi:10.1002/hbm.20127
42. Simmonds DJ, Pekar JJ, Mostofsky SH. Meta-analysis of Go/No-go tasks demonstrating that fMRI activation associated with response inhibition is task-dependent. Neuropsychologia (2008) 46(1):224-32. doi:10.1016/j.neuropsychologia.2007.07.015
43. Olson IR, Berryhill M. Some surprising findings on the involvement of the parietal lobe in human memory. Neurobiol Learn Mem (2009) 91(2):155-65. doi:10.1016/j.nlm.2008.09.006
44. Nickel J, Seitz RJ. Functional clusters in the human parietal cortex as revealed by an observer-independent meta-analysis of functional activation studies. Anat Embryol (2005) 210(5-6):463-72. doi:10.1007/s00429-005-0037-1
45. Cabeza R, Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci (2000) 12(1):1-47. doi:10.1162/08989290051137585
46. Nathan PJ, Phan KL, Harmer CJ, Mehta MA, Bullmore ET. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr Opin Pharmacol (2014) 14:54-61. doi:10.1016/j.coph.2013.11.009
47. Mehta MA, O'Daly OG. Pharmacological application of fMRI. Methods Mol Biol (2011) 711:551-65. doi:10.1007/978-1-61737-992-5_28
48. Czerniak SM, Sikoglu EM, King JA, Kennedy DN, Mick E, Frazier J, et al. Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review. Harv Rev Psychiatry (2013) 21(3):151-62. doi:10.1097/HRP.0b013e318293749e
49. Stoodley CJ. The cerebellum and cognition: evidence from functional imaging studies. Cerebellum (2012) 11(2):352-65. doi:10.1007/s12311-011-0260-7
50. Haxby JV, Petit L, Ungerleider LG, Courtney SM. Distinguishing the functional roles of multiple regions in distributed neural systems for visual working memory. Neuroimage (2000) 11(5 Pt 1):380-91. doi:10.1006/nimg.2000.0592
51. Soto D, Hodsoll J, Rotshtein P, Humphreys GW. Automatic guidance of attention from working memory. Trends Cogn Sci (2008) 12(9):342-8. doi:10.1016/j.tics.2008.05.007
52. Floresco SB. The nucleus accumbens: an interface between cognition, emotion, and action. Annu Rev Psychol (2015) 66:25-52. doi:10.1146/annurev-psych-010213-115159
53. Miller EK. The prefrontal cortex and cognitive control. Nat Rev Neurosci (2000) 1(1):59-65. doi:10.1038/35036228
54. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp (2005) 25(1):46-59. doi:10.1002/hbm.20131
55. Wager TD, Smith EE. Neuroimaging studies of working memory: a meta-analysis. Cogn Affect Behav Neurosci (2003) 3(4):255-74. doi:10.3758/CABN.3.4.255
56. Rae CL, Hughes LE, Weaver C, Anderson MC, Rowe JB. Selection and stopping in voluntary action: a meta-analysis and combined fMRI study. Neuroimage (2014) 86:381-91. doi:10.1016/j.neuroimage.2013.10.012
57. Moher D, Liberati A, TetzlaffJ, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 6(7):e1000097. doi:10.1371/journal.pmed.1000097
58. Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase (2003) 9(3):274-82. doi:10.1076/neur.9.3.274.15563
59. Aasen I, Kumari V, Sharma T. Effects of rivastigmine on sustained attention in schizophrenia: an fMRI study. J Clin Psychopharmacol (2005) 25(4):311-7. doi:10.1097/01.jcp.0000169267.36797.76
60. Kumari V, Aasen I, Ffytche D, Williams SC, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. NeuroImage (2006) 29(2):545-56. doi:10.1016/j.neuroimage.2005.08.013
61. Pavuluri MN, Passarotti AM, Harral EM, Sweeney JA. Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. J Clin Psychiatry (2010) 71(11):1526-34. doi:10.4088/JCP.09m05504yel
62. Pavuluri MN, Ellis JA, Wegbreit E, Passarotti AM, Stevens MC. Pharmacotherapy impacts functional connectivity among affective circuits during response inhibition in pediatric mania. Behav Brain Res (2012) 226(2):493-503. doi:10.1016/j.bbr.2011.10.003
63. Schneider MR, Klein CC, Weber W, Bitter SM, Elliott KB, Strakowski SM, et al. The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder. Psychiatry Res (2014) 223(3):268-70. doi:10.1016/j.pscychresns.2014.04.011
64. Walsh ND, Williams SC, Brammer MJ, Bullmore ET, Kim J, Suckling J, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry (2007) 62(11):1236-43. doi:10.1016/j.biopsych.2006.12.022
65. Aizenstein HJ, Butters MA, Wu M, Mazurkewicz LM, Stenger VA, Gianaros PJ, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry (2009) 17(1):30-42. doi:10.1097/JGP.0b013e31817b60af
66. Wagner G, Koch K, Schachtzabel C, Sobanski T, Reichenbach JR, Sauer H, et al. Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression. J Psychiatry Neurosci (2010) 35(4):247-57. doi:10.1503/jpn.090081
67. Gyurak A, Patenaude B, Korgaonkar MS, Grieve SM, Williams LM, Etkin A. Frontoparietal activation during response inhibition predicts remission to antidepressants in patients with major depression. Biol Psychiatry (2016) 79(4):274-81. doi:10.1016/j.biopsych.2015.02.037
68. van der Wee NJ, Ramsey NF, van Megen HJ, Denys D, Westenberg HG, Kahn RS. Spatial working memory in obsessive-compulsive disorder improves with clinical response: a functional MRI study. Eur Neuropsychopharmacol (2007) 17(1):16-23. doi:10.1016/j.euroneuro.2006.04.012
69. Han JY, Kang DH, Gu BM, Jung WH, Choi JS, Choi CH, et al. Altered brain activation in ventral frontal-striatal regions following a 16-week pharmacotherapy in unmedicated obsessive-compulsive disorder. J Korean Med Sci (2011) 26(5):665-74. doi:10.3346/jkms.2011.26.5.665
70. Snitz BE, MacDonald A III, Cohen JD, Cho RY, Becker T, Carter CS. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry (2005) 162(12):2322-9. doi:10.1176/appi.ajp.162.12.2322
71. Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, et al. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci (2006) 256(8):522-31. doi:10.1007/s00406-006-0687-x
72. Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res (2009) 172(1):16-23. doi:10.1016/j.pscychresns.2008.06.003
73. Keedy SK, Reilly JL, Bishop JR, Weiden PJ, Sweeney JA. Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia. Schizophr Bull (2015) 41(2):355-65. doi:10.1093/schbul/sbu071
74. Ikuta T, Robinson DG, Gallego JA, Peters BD, Gruner P, Kane J, et al. Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. Psychiatry Res (2014) 221(2):127-34. doi:10.1016/j.pscychresns.2013.09.010
75. Wilcox CE, Mayer AR, Bogenschutz MP, Ling J, Dekonenko C, Cumbo H. Cognitive control network function in alcohol use disorder before and during treatment with lorazepam. Subst Use Misuse (2015) 50(1):40-52. doi:10.3109/10826084.2014.957771
76. Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN, et al. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study. Drug Alcohol Depend (2013) 133(3):852-6. doi:10.1016/j.drugalcdep.2013.09.003
77. Grant JE, Odlaug BL, Chamberlain SR, Hampshire A, Schreiber LR, Kim SW. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol (2013) 23(11):1587-96. doi:10.1016/j.euroneuro.2013.07.008
78. Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry (2010) 67(8):715-21. doi:10.1016/j.biopsych.2010.01.016
79. Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, et al. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology (2010) 35(4):938-42. doi:10.1038/npp.2009.196
80. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry (2011) 69(1):7-11. doi:10.1016/j.biopsych.2010.07.004
81. Schulz KP, Fan J, Bedard AC, Clerkin SM, Ivanov I, Tang CY, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (2012) 69(9):952-61. doi:10.1001/archgenpsychiatry.2011.2053
82. Bush G, Holmes J, Shin LM, Surman C, Makris N, Mick E, et al. Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study. Psychiatry Res (2013) 211(1):88-91. doi:10.1016/j.pscychresns.2012.09.004
83. Chou TL, Chia S, Shang CY, Gau SS. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naive children with attention deficit/hyperactivity disorder: a counting Stroop functional MRI study. Eur Neuropsychopharmacol (2015) 25(12):2300-10. doi:10.1016/j.euroneuro.2015.08.024
84. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol (2008) 28(1):59-63. doi:10.1097/jcp.0b013e318161318f
85. Bedard AC, Schulz KP, Krone B, Pedraza J, Duhoux S, Halperin JM, et al. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study. Psychiatry Res (2015) 231(3):353-6. doi:10.1016/j.pscychresns.2015.01.012
86. Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discov Today (2013) 18(23-24):1185-99. doi:10.1016/j.drudis.2013.09.005
87. Nees F. The nicotinic cholinergic system function in the human brain. Neuropharmacology (2015) 96(Pt B):289-301. doi:10.1016/j.neuropharm.2014.10.021
88. Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(8):1810-5. doi:10.1016/j.pnpbp.2008.08.001
89. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol (2007) 30(1):3-12. doi:10.1097/01.WNF.0000240940.67241.F6
90. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (2005) 181(2):358-63. doi:10.1007/s00213-005-2235-1
91. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry (2002) 51(5):349-57. doi:10.1016/S0006-3223(01)01342-7
92. Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol (2004) 7(2):117-23. doi:10.1017/S1461145703004024
93. Goekoop R, Scheltens P, Barkhof F, Rombouts SA. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain (2006) 129(Pt 1):141-57. doi:10.1093/brain/awh671
94. Miettinen PS, Jauhiainen AM, Tarkka IM, Pihlajamaki M, Grohn H, Niskanen E, et al. Long-term response to cholinesterase inhibitor treatment is related to functional MRI response in Alzheimer's disease. Dement Geriatr Cogn Disord (2015) 40(5-6):243-55. doi:10.1159/000435948
95. Pihlajamaki M, Tanila H, Hanninen T, Kononen M, Laakso M, Partanen K, et al. Verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study. Ann Neurol (2000) 47(4):470-6. doi:10.1002/1531-8249(200004)47:4<470::AID-ANA10>3.0.CO;2-M
96. Shao Z, Janse E, Visser K, Meyer AS. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol (2014) 5:772. doi:10.3389/fpsyg.2014.00772
97. Bentley P, Driver J, Dolan RJ. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. Brain (2009) 132(Pt 9):2356-71. doi:10.1093/brain/awp176
98. Pa J, Berry AS, Compagnone M, Boccanfuso J, Greenhouse I, Rubens MT, et al. Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. Ann Neurol (2013) 73(6):762-73. doi:10.1002/ana.23874
99. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs (2010) 24(4):303-17. doi:10.2165/11530260-000000000-00000
100. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry (1995) 38(1):22-33. doi:10.1016/0006-3223(94)00252-X
101. D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, et al. Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry (2012) 169(3):326-34. doi:10.1176/appi.ajp.2011.11020189
102. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry (2003) 160(1):118-27. doi:10.1176/appi.ajp.160.1.118
103. Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, Lester RA. Desensitization of nicotinic receptors in the central nervous system. Ann N Y Acad Sci (1999) 868:620-3. doi:10.1111/j.1749-6632.1999.tb11335.x
104. Gentry CL, Wilkins LH Jr, Lukas RJ. Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human alpha4beta2-and alpha4beta4-nicotinic acetylcholine receptors. J Pharmacol Exp Ther (2003) 304(1):206-16. doi:10.1124/jpet.102.041756
105. Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, et al. In vivo evidence for beta2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry (2014) 76(6):495-502. doi:10.1016/j.biopsych.2013.11.001
106. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res (2002) 956(2):349-57. doi:10.1016/S0006-8993(02)03570-9
107. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci U S A (1999) 96(23):13432-7. doi:10.1073/pnas.96.23.13432
108. Schlagenhauf F, Dinges M, Beck A, Wustenberg T, Friedel E, Dembler T, et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res (2010) 118(1-3):189-200. doi:10.1016/j.schres.2010.01.022
109. Sutherland MT, Ray KL, Riedel MC, Yanes JA, Stein EA, Laird AR. Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies. Biol Psychiatry (2015) 78(10):711-20. doi:10.1016/j.biopsych.2014.12.021
110. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2009) 65(2):144-9. doi:10.1016/j.biopsych.2008.08.028
111. Rhodes JD, Hawk LW Jr, Ashare RL, Schlienz NJ, Mahoney MC. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. Psychopharmacology (2012) 223(2):131-8. doi:10.1007/s00213-012-2700-6
112. Ashare RL, McKee SA. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol (2012) 20(1):63-70. doi:10.1037/a0025594
113. Mocking RJ, Patrick Pflanz C, Pringle A, Parsons E, McTavish SF, Cowen PJ, et al. Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. Neuropsychopharmacology (2013) 38(3):476-84. doi:10.1038/npp.2012.205
114. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 165(8):1040-7. doi:10.1176/appi.ajp.2008.07071135
115. Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract (2014) 20(1):12-24. doi:10.1097/01.pra.0000442935.15833.c5
116. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 68(12):1195-206. doi:10.1001/archgenpsychiatry.2011.83
117. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2012) 37(3):660-8. doi:10.1038/npp.2011.238
118. Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, et al. Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PLoS One (2016) 11(1):e0143490. doi:10.1371/journal.pone.0143490
119. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 110(1-3):149-55. doi:10.1016/j.schres.2009.02.001
120. Wing VC, Wass CE, Bacher I, Rabin RA, George TP. Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Schizophr Res (2013) 149(1-3):190-1. doi:10.1016/j.schres.2013.06.032
121. Livingstone PD, Srinivasan J, Kew JN, Dawson LA, Gotti C, Moretti M, et al. Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci (2009) 29(3):539-50. doi:10.1111/j.1460-9568.2009.06613.x
122. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol (2007) 74(8):1235-46. doi:10.1016/j.bcp.2007.07.032
123. Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci (2004) 24(50):11244-52. doi:10.1523/JNEUROSCI.3009-04.2004
124. Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR, et al. Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry (2011) 50(8):749-62.e39. doi:10.1016/j.jaac.2011.05.011
125. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord (2010) 122(1-2):1-9. doi:10.1016/j.jad.2009.10.033
126. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2012) 37(1):4-15. doi:10.1038/npp.2011.181
127. Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res (2004) 1029(1):41-7. doi:10.1016/j.brainres.2004.09.016
128. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res (2005) 63(2-3):141-9. doi:10.1016/j.eplepsyres.2005.02.002
129. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: an in vivo microdialysis study. Brain Res (1992) 594(1):138-42. doi:10.1016/0006-8993(92)91038-G
130. Loscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res (1993) 18(4):485-502. doi:10.1007/BF00967253
131. Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry (2002) 7(7):726-33. doi:10.1038/sj.mp.4001087
132. Soeiro-de-Souza MG, Henning A, Machado-Vieira R, Moreno RA, Pastorello BF, da Costa Leite C, et al. Anterior cingulate glutamate-glutamine cycle metabolites are altered in euthymic bipolar I disorder. Eur Neuropsychopharmacol (2015) 25(12):2221-9. doi:10.1016/j.euroneuro.2015.09.020
133. Spencer AE, Uchida M, Kenworthy T, Keary CJ, Biederman J. Glutamatergic dysregulation in pediatric psychiatric disorders: a systematic review of the magnetic resonance spectroscopy literature. J Clin Psychiatry (2014) 75(11):1226-41. doi:10.4088/JCP.13r08767
134. Strawn JR, Patel NC, Chu WJ, Lee JH, Adler CM, Kim MJ, et al. Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry (2012) 51(6):642-51. doi:10.1016/j.jaac.2012.03.009
135. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol (2015) 19(2):yv082. doi:10.1093/ijnp/pyv082
136. Gohier B, Ferracci L, Surguladze SA, Lawrence E, El Hage W, KefiMZ, et al. Cognitive inhibition and working memory in unipolar depression. J Affect Disord (2009) 116(1-2):100-5. doi:10.1016/j.jad.2008.10.028
137. Drueke B, Schlaegel SM, Seifert A, Moeller O, Grunder G, Gauggel S, et al. The role of 5-HT in response inhibition and re-engagement. Eur Neuropsychopharmacol (2013) 23(8):830-41. doi:10.1016/j.euroneuro.2013.05.005
138. Klaassens BL, van Gorsel HC, Khalili-Mahani N, van der Grond J, Wyman BT, Whitcher B, et al. Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity. Neuroimage (2015) 122:440-50. doi:10.1016/j.neuroimage.2015.08.012
139. Macoveanu J, Hornboll B, Elliott R, Erritzoe D, Paulson OB, Siebner H, et al. Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology (2013) 38(6):996-1005. doi:10.1038/npp.2012.264
140. Matsuo K, Glahn DC, Peluso MA, Hatch JP, Monkul ES, Najt P, et al. Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. Mol Psychiatry (2007) 12(2):158-66. doi:10.1038/sj.mp.4001894
141. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol (1987) 7(6 Suppl):24S-35S. doi:10.1097/00004714-198712001-00003
142. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol (2000) 14(2):177-85. doi:10.1177/026988110001400208
143. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp (2004) 22(3):246-60. doi:10.1002/hbm.20035
144. Smith HR, Beveridge TJ, Porrino LJ. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience (2006) 138(2):703-14. doi:10.1016/j.neuroscience.2005.11.033
145. Marazziti D, Marracci S, Palego L, Rotondo A, Mazzanti C, Nardi I, et al. Localization and gene expression of serotonin 1A (5HT1A) receptors in human brain postmortem. Brain Res (1994) 658(1-2):55-9. doi:10.1016/S0006-8993(09)90010-5
146. Nandam LS, Hester R, Bellgrove MA. Dissociable and common effects of methylphenidate, atomoxetine and citalopram on response inhibition neural networks. Neuropsychologia (2014) 56:263-70. doi:10.1016/j.neuropsychologia.2014.01.023
147. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport (1997) 8(4):1057-61. doi:10.1097/00001756-199703030-00048
148. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 57(3):249-58. doi:10.1001/archpsyc.57.3.249
149. Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol (2006) 9(2):135-45. doi:10.1017/S1461145705005924
150. Sambataro F, Blasi G, Fazio L, Caforio G, Taurisano P, Romano R, et al. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacology (2010) 35(4):904-12. doi:10.1038/npp.2009.192
151. Hertel P, Nomikos GG, Iurlo M, Svensson TH. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (1996) 124(1-2):74-86. doi:10.1007/BF02245607
152. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 76(5):1521-31. doi:10.1046/j.1471-4159.2001.00154.x
153. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry (2000) 48(3):229-37. doi:10.1016/S0006-3223(00)00850-7
154. Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem (2014) 128(6):938-49. doi:10.1111/jnc.12512
155. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (1999) 141(3):267-78. doi:10.1007/s002130050834
156. Magalona SC, Rasetti R, Chen J, Chen Q, Gold I, Decot H, et al. Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. CNS Drugs (2013) 27(8):663-73. doi:10.1007/s40263-013-0082-x
157. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology (2007) 32(5):1011-20. doi:10.1038/sj.npp.1301227
158. Huotari M, Gainetdinov R, Mannisto PT. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol Toxicol (1999) 85(5):233-8. doi:10.1111/j.1600-0773.1999.tb02014.x
159. Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, Mannisto PT. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur J Pharmacol (1998) 356(2-3):127-37. doi:10.1016/S0014-2999(98)00524-X
160. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci (2004) 24(23):5331-5. doi:10.1523/JNEUROSCI.1124-04.2004
161. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 27(5):699-711. doi:10.1016/S0893-133X(02)00346-9
162. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci (2001) 21(10):3628-38.
163. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry (2010) 49(10):1011-23. doi:10.1016/j.jaac.2010.06.015
164. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem (2010) 114(1):259-70. doi:10.1111/j.1471-4159.2010.06750.x
165. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res (2005) 77(1):43-58. doi:10.1016/j.schres.2004.12.019
166. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 70(4):518-25. doi:10.4088/JCP.08m04358
167. Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry (2011) 69(12):e89-99. doi:10.1016/j.biopsych.2011.01.027
168. Ruggiero S, Clavenna A, Reale L, Capuano A, Rossi F, Bonati M. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol (2014) 24(10):1578-90. doi:10.1016/j.euroneuro.2014.08.001
169. McKee SA, Potenza MN, Kober H, Sofuoglu M, Arnsten AF, Picciotto MR, et al. A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. J Psychopharmacol (2015) 29(3):300-11. doi:10.1177/0269881114562091
170. Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, et al. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci U S A (2009) 106(31):13040-5. doi:10.1073/pnas.0905267106
171. Cole DM, Oei NY, Soeter RP, Both S, van Gerven JM, Rombouts SA, et al. Dopamine-dependent architecture of cortico-subcortical network connectivity. Cereb Cortex (2013) 23(7):1509-16. doi:10.1093/cercor/bhs136
172. Franco R, Casadó-Anguera V, Muñoz A, Petrovic M, Navarro G, Moreno E, et al. Hints on the lateralization of dopamine binding to D1 receptors in rat striatum. Mol Neurobiol (2015). doi:10.1007/s12035-015-9468-8
173. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, et al. Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. Brain Struct Funct (2014) 219(1):171-83. doi:10.1007/s00429-012-0492-4
174. Capper-Loup C, Rebell D, Kaelin-Lang A. Hemispheric lateralization of the corticostriatal glutamatergic system in the rat. J Neural Transm (Vienna) (2009) 116(9):1053-7. doi:10.1007/s00702-009-0265-2
175. Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, et al. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology (2015) 232(11):1859-66. doi:10.1007/s00213-014-3813-x
176. Kumar G, Olley J, Steckler T, Talpos J. Dissociable effects of NR2A and NR2B NMDA receptor antagonism on cognitive flexibility but not pattern separation. Psychopharmacology (2015) 232(21-22):3991-4003. doi:10.1007/s00213-015-4008-9
177. Alt A, Pendri A, Bertekap RL Jr, Li G, Benitex Y, Nophsker M, et al. Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors. J Pharmacol Exp Ther (2016) 356(2):293-304. doi:10.1124/jpet.115.226910